Full text of press release Rising Bioscienc
Post# of 266
(Total Views: 729)
Posted On: 07/04/2018 2:28:58 AM
Full text of press release
Rising Biosciences Launches RBS0346 Clinical Strength Dulcis Stem Cell Cream on Amazon; Advancements in FDA Approvals Indicate Bright Future for Cannophen™
Print
July 02, 2018 11:00 ET | Source: Rising Biosciences, Inc.
photo-release
Marijuana legalization by state
Marijuana legalization by state
Recreational, medical and CBD by state
SANDUSKY, Ohio, July 02, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Rising Biosciences, Inc. (RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that its revolutionary RBS0346 Clinical Strength Dulcis Stem Cell Cream will be available on Amazon.com in the coming days.
This marks the Company’s second product on Amazon’s virtual shelves so far this year. “Our RBS0238 Clinical Strength Peptide Complex hit the Top Ten in its category only days after launch and exceeded our own expectations as we sold out in the first week before quickly replenishing our inventory. We are confident the Stem Cell Cream will follow suit in exceeding expectations and are well prepared with inventory accordingly,” states CEO Robert Weber.
The Company has also reached advanced negotiations to contract with Producers/Processors in MMJ States to License and Market Cannophen™ and other THC products. “These relationships can have an enormous impact on revenues for our company and shareholders,” states Weber. “We are confident that we’ll have strategic alliances and partnerships in place to effect RBII products on dispensary shelves by the end of Q3 2018.”
“Last week, the FDA recently approved the use of an oral cannabidiol (CBD) solution called Epidiolex for the treatment of two rare forms of epilepsy: Lennox–Gastaut syndrome and Dravet syndrome, in patients aged 2 and older. It's the first time the regulatory body had greenlit a medication based on natural – not synthesized – CBD, and some experts are hailing this approval as a major step forward for the medical cannabis industry.”
"We see this as a tipping point," says COO Arthur Hall. "It rapidly destigmatizes what cannabis can do. It is a monumental step in terms of overall regulatory climate shifts and indicative of future opportunities for a company like Rising Biosciences.”
There are now 30 states with some kind of legalized marijuana provision in place. Oklahoma became the latest state to legalize MMJ and there are other proposals to fully legalize the drug at the federal level, including one by New Jersey Sen. Cory Booker, an oft-mentioned potential 2020 presidential candidate.
Weber concludes: “We will continue an assertive approach here in line with legally available channels as we continue to identify revolutionary formulas and applications while ensuring distribution outlets all the while.”
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...2550cf1c21.
Rising Biosciences Launches RBS0346 Clinical Strength Dulcis Stem Cell Cream on Amazon; Advancements in FDA Approvals Indicate Bright Future for Cannophen™
July 02, 2018 11:00 ET | Source: Rising Biosciences, Inc.
photo-release
Marijuana legalization by state
Marijuana legalization by state
Recreational, medical and CBD by state
SANDUSKY, Ohio, July 02, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE – Rising Biosciences, Inc. (RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that its revolutionary RBS0346 Clinical Strength Dulcis Stem Cell Cream will be available on Amazon.com in the coming days.
This marks the Company’s second product on Amazon’s virtual shelves so far this year. “Our RBS0238 Clinical Strength Peptide Complex hit the Top Ten in its category only days after launch and exceeded our own expectations as we sold out in the first week before quickly replenishing our inventory. We are confident the Stem Cell Cream will follow suit in exceeding expectations and are well prepared with inventory accordingly,” states CEO Robert Weber.
The Company has also reached advanced negotiations to contract with Producers/Processors in MMJ States to License and Market Cannophen™ and other THC products. “These relationships can have an enormous impact on revenues for our company and shareholders,” states Weber. “We are confident that we’ll have strategic alliances and partnerships in place to effect RBII products on dispensary shelves by the end of Q3 2018.”
“Last week, the FDA recently approved the use of an oral cannabidiol (CBD) solution called Epidiolex for the treatment of two rare forms of epilepsy: Lennox–Gastaut syndrome and Dravet syndrome, in patients aged 2 and older. It's the first time the regulatory body had greenlit a medication based on natural – not synthesized – CBD, and some experts are hailing this approval as a major step forward for the medical cannabis industry.”
"We see this as a tipping point," says COO Arthur Hall. "It rapidly destigmatizes what cannabis can do. It is a monumental step in terms of overall regulatory climate shifts and indicative of future opportunities for a company like Rising Biosciences.”
There are now 30 states with some kind of legalized marijuana provision in place. Oklahoma became the latest state to legalize MMJ and there are other proposals to fully legalize the drug at the federal level, including one by New Jersey Sen. Cory Booker, an oft-mentioned potential 2020 presidential candidate.
Weber concludes: “We will continue an assertive approach here in line with legally available channels as we continue to identify revolutionary formulas and applications while ensuring distribution outlets all the while.”
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...2550cf1c21.
(0)
(0)Rising India Inc (RBII) Stock Research Links
Louis Pasteur -- chance favours only the prepared mind.
Lecture, University of Lille (7 December 1854)
Lecture, University of Lille (7 December 1854)